Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Biliary tract cancer (cholangiocarcinoma), drawn from the whole corpus: 229 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
FGFR inhibitor resistance.
Also on OnCo: Resistance atlas · Lines of therapy.
Late diagnosis.
Background: CA 19-9. Also on OnCo: Symptoms and red flags · Early detection roadmap.
Median survival in advanced disease is still barely a year; the immunotherapy benefit is a small tail with no predictive biomarker.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
FGFR inhibitor resistance (polyclonal kinase-domain mutations) limits benefit to ~7-9 months; sequencing next-generation agents is unproven.
Also on OnCo: Resistance atlas · Lines of therapy.
Second-line chemotherapy is weak (FOLFOX) and evidence for liposomal irinotecan is contradictory.
Gallbladder cancer is under-represented in trials despite distinct biology and high HER2 prevalence.
Early detection in primary sclerosing cholangitis and fluke-endemic regions is unsolved; CA 19-9 is non-specific.
Background: CA 19-9. Also on OnCo: Symptoms and red flags · Early detection roadmap.
Molecular testing is slow and tissue is scarce from brushings; liquid biopsy adoption lags.
Adjuvant evidence rests on a technically negative trial (BILCAP); immunotherapy adjuvant trials are ongoing.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 55 changes by month →When this page itself was last checked or edited.
NRG1-fusion cholangiocarcinoma
HER2-positive (IHC 3+) unresectable locally advanced or metastatic biliary tract cancer after at least one line of systemic treatment; MHRA 19 February 2026, NICE TA1153 published 7 May 2026 with a commercial arrangement
NRG1-fusion cholangiocarcinoma
Contrast CT/MRI with MRCP; ERCP or EUS-guided biopsy; molecular profiling (DNA + RNA NGS) for all advanced disease; biliary drainage if jaundiced. (NCCN Molecular testing recommended (category 2A))
A milestone in how this cancer is treated.